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Depression Questionnaire was administered at baseline and follow up
(when 322 men and 320 women were seen).
Results: The mean age of males and females was 64.3 years and 65.6
years respectively. Circulating 25(OH)D concentrations were higher in
those attending clinic in summer/autumn compared to those attending
in winter/spring (p<0.001). 12.1% men and 17.2% women were
vitamin D deficient (concentration <25 nmol/l) and 45.7% men and
47.0% women had concentrations between 40 and 75 nmol/l. We
found no relationship between pain at baseline and circulating
25(OH)D concentration in either sex. Similarly there was no relationship
between depression score and vitamin D status. However, women
who had the highest circulating 25(OH)D concentrations (>75 nmol/l)
had the highest risk of incident bodily pain (OR 6.31 CI 1.15, 34.7,
p¼0.034) after adjustment for age, body mass index, season of
baseline 25(OH)D and of 4-year assessment, social class, cigarette
and alcohol consumption, physical activity, number of co-morbidities,
cod-liver oil intake, physician diagnosed osteoarthritis and fracture
since aged 45. No such relationships were observed in men.
Conclusions: We report an unexpected finding of a positive
association between development of bodily pain and vitamin D
concentration measured 4 years prior. Although confounding by
indication remains a possibility, our results remained after adjustment
for age, body mass index, season of measurement, social class,
cigarette and alcohol consumption, physical activity, number of co-
morbidities, cod-liver oil intake, OA, and osteoporotic fracture; further
studies are now indicated to reproduce this finding.
Disclosure statement: The authors have declared no conflicts of
interest.
133. ARTHRITIS HURTS: A STUDY OF HOW ARTHRITIS
PAIN AFFECTS PEOPLE LIVING WITH ARTHRITIS IN
THEIR EVERYDAY LIFE
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Background: Whilst we know pain affects the majority of people living
with arthritis in the UK, a user-led arthritis charity wanted to know more
about how this pain affects them in their everyday life in order to raise
public awareness and take the necessary steps to improve the
provision of services in this area. Arthritis is the biggest cause of
physical disability in the UK affecting up to 10 million people, including
12,000 children, and accounting for 30% of GP visits. It carries a huge
economic as well as human and social cost, estimated at £7 billion
annually in terms of lost labour in 2007. It is the most common cause of
chronic pain in the UK, with pain being the most common symptom of
living with arthritis. An average of 85% of contacts to the charity’s
helpline are about pain. Around 5,150 people per year received
information about pain management via the helpline.
Methods: An email was sent directly to 14,776 of the charity’s
supporters living with arthritis inviting them to take part in the survey.
This online survey was also promoted from 24 March to 5 April 2010 to
supporters via the charity’s website home page, social networking
outlets and via its on line discussion forum. A total of 2,263 surveys
were analysed.
Results: Out of the 2,263 responses collected, 78.7% were female
and 89.3% of the participants were white British. 59.7% were aged
between 45 and 64 years and 82% were of working age. The results of
this survey showed that a majority of respondents are putting up with
severe levels of pain on a regular basis. 56.7% stated they would wait
until it was ‘often unbearable and frequently stops me doing daily
activities’. 77% of participants stated their arthritis pain prevents them
from sleeping through the night. 57% stated their every day arthritis
pain caused them difficulties coping at work. We asked people
whether pain caused them difficulty carrying out certain activities.
When pain is everyday pain, 50% of people had difficulty getting out of
bed, 41% had difficulty making a cup of tea, 58% had difficulty
sleeping, 42% having a hug, 49% having sex.
When pain is at its most severe, 62% of people had difficulty
getting out of bed, 65% of people had difficulty making a cup of tea,
58% had difficulty sleeping, 65% had difficulty having a hug, 63%
having sex.
Conclusions: These figures indicate that people have to endure
significant limitations in everyday life due to unmanaged pain. Greater
awareness of arthritis and the importance of seeking proper medical
attention would lead to earlier interventions and therefore mitigate this
situation.
Acknowledgments: This work has been supported by an educational
grant from MSD, by way of the secondment of A K Gilbert, researcher
and employee of MSD.
Disclosure statement: A.G. has received research support from MSD
and is the employer of Annie Gilbert. All other authors have declared
no conflicts of interest.
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Background: Rheumatoid arthritis (RA) causes progressive joint
damage and functional disability. Studies on factors affecting joint
damage as clinical outcome are lacking in Africa. The aim of the
present study was to identify predictors of joint damage in adult South
Africans with established RA.
Methods: A cross-sectional study of 100 black patients with RA of >5
years were assessed for joint damage using a validated clinical
method, the RA articular damage (RAAD) score. Potential predictors of
joint damage that were documented included socio-demographics,
smoking, body mass index (BMI), disease duration, delay in disease
modifying antirheumatic drug (DMARD) initiation, global disease
activity as measured by the disease activity score (DAS28), erythrocyte
sedimentation rate (ESR), C reactive protein (CRP), and autoantibody
status. The predictive value of variables was assessed by univariate
and stepwise multivariate regression analyses. A p value <0.05 was
considered significant.
Results: The mean (SD) age was 56 (9.8) years, disease duration 17.5
(8.5) years, educational level 7.5 (3.5) years and DMARD lag was 9 (8.8)
years. Female to male ratio was 10:1. The mean (SD) DAS28 was 4.9
(1.5) and total RAAD score was 28.3 (12.8). The mean (SD) BMI was
27.2 kg/m2 (6.2) and 93% of patients were rheumatoid factor (RF)
positive. More than 90% of patients received between 2 to 3 DMARDs.
Significant univariate predictors of a poor RAAD score were increasing
age (p¼ 0.001), lower education level (p¼ 0.019), longer disease
duration (p<0.001), longer DMARD lag (p¼0.014), lower BMI
(p¼0.025), high RF titre (p<0.001) and high ESR (p¼0.008). The
multivariate regression analysis showed that the only independent
significant predictors of a higher mean RAAD score were older age at
disease onset (p¼ 0.04), disease duration (p<0.001) and RF titre
(p<0.001). There was also a negative association between BMI and
the mean total RAAD score (p¼ 0.049).
Conclusions: Patients with longstanding established RA have more
severe irreversible joint damage as measured by the clinical RAAD
score, contrary to other studies in Africa. This is largely reflected by a
delay in the initiation of early effective treatment. Independent of
disease duration, older age at disease onset and a higher RF titre are
strongly associated with more joint damage. The inverse association
between BMI and articular damage in RA has been observed in several
studies using radiographic damage scores. The mechanisms under-
lying this paradoxical association are still widely unknown but
adipokines have recently been suggested to play a role.
Disclosure statement: C.I. has received a research grant from the
Connective Tissue Diseases Research Fund, University of the
Witwatersrand. All other authors have declared no conflicts of interest.
135. WHAT ARE THE PREDICTORS FOR OSTEOPOROSIS
AT DIFFERENT SITES IN RHEUMATOID ARTHRITIS?
Jonathan Barnes1, C. Donnison1, M. Scott1, Peter Bartholomew1,
Martin Rynne1, Jennifer Hamilton1, V. Saravanan1, Carol Heycock1
and Clive Kelly1
1Rheumatology, QEH Gateshead, Gateshead, United Kingdom
Background: Osteoporosis is common in patients with rheumatoid
arthritis (RA) and is associated with an increased fracture risk. Indeed,
RA is recognised as a specific risk factor in the FRAX score
calculation. Previous work by our group has shown a high prevalence
of osteoporosis in cortical bone using peripheral bone mineral density
(BMD) scanning. This was related to disease duration and steroid use.
We wished to assess the prevalence of axial osteoporosis in our
current rheumatoid population, and to perform multivariate analysis to
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calculate which risk factors were predictors for osteoporosis at hip and
spine.
Methods: We measured BMD at hip and spine using a Hologic
Discovery C scanner in 196 patients with RA who were over 50 or who
had at least a 10 year history of the disease. We recorded the patients’
age, gender, disease duration, disease activity score in 28 joints
(DAS28), ESR, presence of erosions, RF and CCP levels, together with
all treatment including steroid dose and duration. We calculated the
overall prevalence of osteoporosis and performed a multivariate
analysis, assuming a linear model for continuous variables, to assess
the factors predictive of reduced BMD in individuals.
Results: Osteoporosis (T score < -2.5) was present at either hip or
spine in 61 RA patients (31%). Multivariate analysis showed that
the predictors for decreased BMD at the spine were female gender
and CCP positivity, while decreased BMD at the hip was associated
with female gender, age and ESR. In addition, use of bisphosphonates
was associated with lower BMD at both sites, as would be expected.
We also noted a higher than expected number of patients with
degenerative spinal disease which reduced the amount of reliable data
available at this site.
Conclusions: Osteoporosis at hip and/or spine is common in patients
with RA over 10 years duration. Bisphosphonate therapy appears to be
appropriately targeted. However, there appear to be site specific risk
factor profiles for osteoporosis in RA. Disease duration has been
previously associated with peripheral bone loss; our present work
suggests that disease severity is important in predicting spinal BMD
whilst disease activity influences bone density at the hip. Females are
at greater risk of osteoporosis at both these sites. Degenerative spinal
disease may be more common in RA and this needs to be considered
when assessing bone density at this site.
Disclosure statement: The authors have declared no conflicts of
interest.
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Background: Coordinated expression of BAFF binding receptors
(BBRs) (BAFF-R, TACI, BCMA) control differentiation of B cells into
immunoglobulin (Ig) secreting cells. We have reported that i) BAFF
levels rise after B cell depletion with rituximab (RTX) in patients with
RA, remaining raised even after B cell return ii) BAFF-R expression in
naı¨ve B cells (NB) and memory B cells (MB) is reduced after RTX and
related to clinical relapse independently of serum BAFF levels or time
to relapse after B cell return iii) Class-switch recombination (CSR) and
autoantibody production is also related to clinical relapse after RTX.
When B cells differentiate into Ig secreting cells, BAFF-R is lost and
BCMA up-regulated. TACI is induced upon B cell activation, being
present on most MB. Although expressed on <20% activated (CD86þ)
NB, TACI is more related to CSR and plasma cell differentiation. BBR
expression was therefore investigated in relation to clinical relapse in
RA patients after RTX.
Methods: Phenotypic analysis of BAFF-R, TACI and BCMA expres-
sion on PBMC were performed using combinations of CD19, CD27,
CD38 and IgD (% and mean fluorescence intensity-MFI) in normal
controls (NC) (n¼5) and patients pre (n¼10) and after RTX, classified
as concordant ie relapsing at B cell return (C-R, n¼16), or discordant
(relapsing>3 months after repopulation; D-R, n¼10) or non-relapsing
after B cell return (D-NR, n¼11).
Results: Mean % of NB cell BAFF-Rþ was significantly lower only in
patients relapsing (C-R: 65.3%, D-R: 89.7%) when compared to NC
(p¼0.027, p¼0.026). Percentage and MFI of MB cell BAFF-Rþ was
significantly lower in all patients when compared to both NC and pre-
RTX (%: p<0.05; MFI:p<0.005). In patients relapsing, % NB cell
TACIþ tended to be higher in C-R than D-R (23.4% vs 9.9%). All
patients pre and after RTX had significantly lower % of TACIþMB cells
when compared to NC (p<0.05). However % of MB cell TACIþwas
significantly higher in D-NR when compare to D-R (p¼0.001). BAFF-R
and BCMA did not always had an inverse correlation in plasma cell
populations after RTX. Finally, C-R patients had higher % of plasma
cells than D-R and D-NR (16.5% vs 2.06% and 1.85; p¼0.03 and
p¼0.06).
Conclusions: Rises in autoantibody levels have been related to
clinical relapse after RTX. Modulation of BBR expression permissive to
plasma cell formation in C-R patients, associated with an earlier down
regulation of BAFF-R and up regulation of TACI on (presumably
activated autoreactive) NB cells may explain clinical relapse closer to
B cell return. Normal BAFF-R expression on NB cells in D-NR patients
may reduce the chance of becoming Ig-producing cells, thereby
lowering the chance of the autoreactive NB population differentiating
into autoantibody producing cells. The consequences of disturbed
BBR expression on B cell selection and the advancement or inhibition
of progression to autoantibody production may help explain timing of
relapse after RTX.
Disclosure statement: The authors have declared no conflicts of
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CLINICAL RESPONSE TO RITUXIMAB
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Background: In patients with RA treated with BCDT, IgA levels do not
decrease to the same extent or in as many patients as IgM or IgG
levels. Preliminary analysis of serum Ig levels in 131 patients in the
UCL cohort of patients with RA showed that IgA levels were actually
raised in 30 RA patients before treatment and did not always normalize
following BCDT. IgG and IgM levels were raised in 29 and 16 patients
respectively, normalizing in most after the first cycle of BCDT. In this
prospective study we investigated whether levels of Ig isotypes at
baseline were associated with clinical pattern of response.
Methods: 131 patients with RA treated with RTX were studied.
Baseline serum Ig levels, CRP, DAS28, CD19þve B cell count at
baseline, 1, 3 and 5 months after first cycle of rituximab, were
collected prospectively. Groups were defined related to baseline total
Ig levels: Normal IgA (0.7-4.0 g/L), High IgA (>4.0 g/L), Normal IgG (7.0-
16.0 g/L), High IgG (>16.0 g/L), Normal IgM (0.4-2.3 g/L), High IgM
(>2.3 g/L). Adequate depletion and B cell repopulation were defined as
having <5 or 5 CD19þ cells/l respectively. Mann Whitney U and
Wilcoxon tests were performed for independent and paired
parameters.
Results: All patients were adequately depleted at 1 month. Baseline
CRP levels were significantly higher in the High IgA and IgG groups
compared with those with normal baseline Igs (p¼0.0002; p¼ 0.03
respectively). Minimum CRP levels reached in all groups were
significantly lower compared to pre-RTX levels (p< 0.0001) but
patients starting with High IgA had a significantly higher minimum
CRP (p¼0.002) and also remained with higher minimum DAS28 when
compared to those starting with Normal IgA (p¼ 0.05). After 5 months,
patients in the High IgA group had significantly more CD19þ cells
(p¼0.003) than those with normal baseline IgA and the proportion of
patients repopulating at 5 months was also significantly greater in the
High IgA group (**p¼0.004, Fisher’s exact test) (Table 1). Baseline
levels of IgM were not correlated with any parameters evaluated.
Conclusions: Baseline levels of Ig may be predictive of the pattern of
clinical response to rituximab. Patients with initially higher total serum
IgA and IgG had significantly higher levels of baseline CRP and those
in the High baseline IgA group had higher minimum DAS28 scores after
rituximab than those with Normal baseline IgA. In addition, a larger
proportion of patients with higher baseline IgA were more likely to have
detectable B cells at 3 and 5 months and also had significantly higher
numbers of repopulating B cells at five months post rituximab despite
successful depletion.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
Baseline
Ig Group
Number and % patients
with CD19þ cells> 5/l
3 months after RTX
Number and % patients
with CD19þ cells> 5/l
5 months after RTX
High IgA 9/26 (34.6) 15/23 (65.2)**
Normal IgA 6/44 (13.6) 13/49 (26.5)**
High IgG 4/20 (20.0) 10/17 (58.8)
Normal IgG 8/40 (20.0) 15/44 (34.1)
**P¼ 0.004, Fisher’s exact test
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138. ASSESSMENT OF SYNOVITIS IN RHEUMATOID
ARTHRITIS AND THE EFFECT OF ULTRASOUND JOINT
COUNTS ON DAS28 VALUES
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1RA Centre, Rheumatology, Guy’s & St Thomas’ NHS Foundation
Trust, London, United Kingdom; 2NIHR Comprehensive Biomedical
Research Centre, Guy’s & St Thomas’ Hospitals & King’s College
London, London, United Kingdom; 3Rheumatology, DMRC Headley
Court, Surrey, United Kingdom
Background: The DAS28 is a composite measure of disease activity in
patients with Rheumatoid Arthritis (RA). Patients with a moderate DAS
28 (3.2-5.1) have ongoing loss of function and continued joint damage.
Current UK treatment guidelines require DAS 28 >5.1 to qualify for
anti-TNF therapy. Ultrasound (US) assessment of joint swelling is more
sensitive than clinical examination, and clinical joint counts may have
moderate interobserver variability. We conducted a study to investi-
gate patients for subclinical synovitis and evaluate effects on DAS28
scores and potential treatment options.
Methods: 20 patients with RA had 28 joint counts performed by a
consultant and a trainee rheumatologist. 10 MCP and PIP joints (total
400 joints) were scanned in two planes with grey scale and power
Doppler US by an independent assessor. Agreement between clinical
examinations and US was assessed by intraclass correlation coeffi-
cients (ICC) and percentage absolute agreement. DAS28 scores were
calculated using both standard joint counts, then substituting the US
swollen joint count or Doppler count for clinical swollen (SJC) or tender
joint counts (TJC).
Results: ICC for SJC and TJC were 0.50 and 0.90, with high
agreement of DAS28 scores (ICC 0.93) between the two observers.
Exact agreement was seen in 187/240 joints (68%) for swelling and
201/240 joints (84%) for tenderness. US detected more synovitis and
joint effusion (349/380 joints, 92%) than clinical swelling (87/380 joints,
23%) (p<0.001). It also detected more vascularity on PD (224/380
joints, 59%), compared to clinical tenderness (94/380 joints, 24%)
(p¼0.0012). There were no significant correlations between clinical
and US scores. The mean DAS 28 based on clinical scores was 4.1
(SD 1.3). This increased to 4.9 (SD 1.3) (p<0.001) when US swelling
was substituted for SJC. The mean DAS 28 increased further and
significantly to 5.7 (SD 0.8) (p<0.001) when US vascularity was also
substituted for TJC.
Conclusions: The consultant detected significantly more swelling than
the trainee, but this had little effect on the DAS 28, due to a low
weighting of swelling in the score. US detected significantly more
synovitis and substitution of US derived counts had a significant effect
on the DAS28. Four additional patients (29%) had a DAS28 >5.1
based on US swelling assessments, and an additional 9 patients had a
DAS28 >5.1 if the Doppler count was additionally substituted for the
clinical tender joint count. We suggest that a large number of RA
patients with moderate DAS 28 scores have significant ongoing
disease activity. This supports the recent BSR guidance that biologic
therapies should be available to patients with moderate disease
activity.
Disclosure statement: B.K. has served on advisory boards for
Abbott, Bristol-Myers Squibb, Centocor, Pfizer, Roche and UCB,
and has received research grants from Abbott, Centocor and Pfizer. All
other authors have declared no conflicts of interest.
TABLE 1. Effects of US joint counts on DAS28 scores
DAS28 <2.6 2.7-3.1 3.2-5.1 >5.1
DAS1 (TJC, SJC) 2 3 10 4
DAS2 (US synovitis count, TJC) 1 0 10 8
DAS3 (US synovitis þ PD counts) 0 0 6 13
139. A COMPARISON OF 3D AND 2D ULTRASOUND IN
THE DETECTION OF SYNOVITIS, EROSIONS AND POWER
DOPPLER ACTIVITY IN RHEUMATOID ARTHRITIS
Louise E. Daniels1, Nicola J. Gullick1, Bruce W. Kirkham1 and
Jonathan Rees1,2
1Department of Rheumatology, Guy’s and St Thomas’ Hospitals,
London, United Kingdom; 2DMRC Headley Court, Surrey,
United Kingdom
Background: Rheumatoid Arthritis (RA) is a common chronic,
symmetrical inflammatory polyarthritis characterised by joint swelling
resulting in damage and reduced physical function. Two-dimensional
(2D) Ultrasound (US) is a highly sensitive and specific tool which has
greatly assisted the diagnosis and determination of clinical activity and
structural damage in RA. 3D US is an emerging imaging modality that
has yet to be studied systematically in relation to arthritis of small joints
in RA. We wanted to determine the utility of 3-D US in comparison to
2-D US in established RA patients in terms of assessment of synovitis
and structural damage.
Methods: 20 patients with a diagnosis of RA were recruited. All
10 MCP and 10 PIP joints were scanned with a 2D and 3D probe. This
gave a total of 400 joints in the 20 patients. Images were scored using
standard semi-quantitative systems for three criteria; synovitis and
joint effusion, power Doppler (PD) and erosions.
Results: Erosions were detected in 70% of joints with 3D US
compared to 47% with 2D US (p¼0.009). Furthermore 3D US
demonstrated greater severity of erosions than was demonstrated in
2D US. 3D US detected synovitis and joint effusions in 96% of joints
compared with 91% with 2D US (p¼0.046). It was not possible
to accurately detect synovial vascularity using 3D PDUS due to
movement artefact from the 3D probe.
Conclusions: 3D US is more sensitive than 2D US for the detection of
synovitis, joint effusions and erosions than 2D US. 3D US may have a
role in confirming disease activity and structural damage in RA over
and above that of 2D US. Further work is required to optimise the PD
feature of 3D US.
Disclosure statement: B.K. has served on advisory boards for and
received research support from Bristol-Myers Squibb, Pfizer, Abbott,
Centocor, Roche and UCB. All other authors have declared no
conflicts of interest.
140. CARDIOVASCULAR DISEASE IN RHEUMATOID
ARTHRITIS IS PREDOMINANTLY DRIVEN BY TRADITIONAL
CARDIOVASCULAR RISK FACTORS
Ian C. Scott1, Deborah Johnson2, David L. Scott3 and
Gabrielle Kingsley2
1Rheumatology, Guy’s and St Thomas’ NHS Trust, London,
United Kingdom; 2Rheumatology, University Hospital of Lewisham,
London, United Kingdom; 3Rheumatology, King’s College Hospital,
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Background: The excessive cardiovascular (CV) risk in rheumatoid
arthritis (RA) is well known. It reflects both the effects of traditional CV
risk factors and systemic inflammation in RA. Currently rheumatolo-
gists mainly focus on reducing systemic inflammation in RA, which
is known to reduce atherosclerosis. Although reducing conventional
risks like hypertension may be equally important they are not always
assessed by rheumatologists. We therefore evaluated the overall
management of CV risk factors in RA patients and examined the
relative contribution of conventional risk factors to CV morbidity.
Methods: We cross-sectionally studied 305 RA patients attending
specialist clinics in South East London. We assessed RA charac-
teristics, screening/treatment of CV risk factors (hypertension, hyper-
lipidaemia, diabetes, obesity, smoking) and RA/CV treatments.
Atherosclerosis was defined as a previous CV event. Factors
associated with atherosclerosis were evaluated using binary logistic
regression.
Results: The patients comprised 81% females of median age 60 years
and median disease duration 8 years. Disease activity was moderate
(mean DAS28 3.45). 28 (9%) had a previous CV event. CV risk factors
were common: hypertension (57%), hyperlipidaemia (30%), diabetes
(11%), ex/current smokers (52%) and obesity (31%). Screening for risk
factors was inadequate: only one third of patients without known
diabetes or hyperlipidaemia had ever had fasting glucose or lipid
levels performed. CV risk factors were undertreated: 52% of patients
on anti-hypertensives had ongoing hypertension. Hyperlipidaemia and
hypertension were significantly associated with atherosclerosis
(Table 1). Indirect markers of long-term inflammation - disease
duration and erosions - were associated with atherosclerosis to a
lesser extent. Hypertension (OR 4.3, 95%CI 1.1-16.8) and disease
duration (OR 1.1, 95%CI 1.0-1.1) retained their significance in a
multivariate model that did not include hyperlipidaemia (as statin use in
CV events may be independent of lipid status).
Conclusions: Although chronic inflammation contributes to athero-
sclerosis in RA, hyperlipidaemia and hypertension are dominant
factors. Despite this association CV risk factors were insufficiently
screened for and under treated in this population. We recommend
rheumatologists should take responsibility for CV risk factor assess-
ment. Once identified they can be treated in primary care.
Disclosure statement: The authors have declared no conflicts of
interest.
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TABLE 1. The significant associations between clinical characteristics and
atherosclerosis
Characteristic Univariate
Analysis
P-value
Multivariate
Analysis
P-value
Univariate Logistic
Regression-Odds
Ratio (95% CI)
Age 0.002 0.682 1.05 (1.02, 1.09)
Erosions 0.056 1.000 2.53 (0.98, 6.52)
Disease Duration 0.000 0.002 1.09 (1.05, 1.13)
Non-Steroidal
Anti-Inflammatory
Drugs
0.032 0.209 0.20 (0.47, 0.87)
Leflunomide 0.015 0.117 3.49 (1.27, 9.59)
Hypertension 0.004 0.038 4.85 (1.63, 14.4)
Hyperlipidaemia 0.000 – 19.1 (6.39, 57.0)
Ex-Smoker 0.017 0.242 2.98 (1.21, 7.32)
141. PERSISTING REMISSION IS ESSENTIAL TO ACHIEVE
LOW HAQ SCORES IN RHEUMATOID ARTHRITIS
Margaret H. Ma1,2, Andrew P. Cope2, David L. Scott1 and
Bruce W. Kirkham2
1Rheumatology, King’s College Hospital, London, United Kingdom;
2Rheumatology, Guy’s and St Thomas’ Hospital, London,
United Kingdom
Background: Remission has become the treatment target in RA.
Goal directed therapy (GDT) targeting remission has the propensity to
reduce disability and minimise radiographic progression. However, the
relative benefits of sustained over intermittent remission are uncertain.
There is also limited data about those patients most likely to achieve
sustained remission. We addressed both these questions using real
life data collected in a clinical practice setting.
Methods: We examined the frequency, predictors and impact of
remission in prospectively collected routine practice data. The dataset
comprised of demographics descriptors, disability (HAQ), disease
activity (DAS28), C-reactive protein (CRP) and Rheumatoid Factor.
DAS28< 2.6 was used as the definition of remission. Sustained
remission is defined as persistent remission over 4 consecutive visits.
One-way ANOVA analysis and Spearman’s correlation were used to
assess the relationship of HAQ and disease activity and logistic
regression analysis was used to evaluate the predictors of sustained
remission.
Results: We studied 316 RA patients followed over 4 consecutive
visits. 249 (79%) were female and their mean age was 56 years (SD
14). 174 patients (55%) were rheumatoid factor positive, 32 patients
(10%) had nodules and 133 patients (42%) had erosions on plain film
x-rays. 45% of patients achieved remission at some point during the
follow-up period. 57 (18%) of patients were in remission at 1 time point
(point remission), 54 (17%) were in remission over 2-3 time points
(intermittent remission) and 31 (10%) of patients were in sustained
remission. Average HAQ and average DAS across the 4 visits were
highly correlated (Spearman’s R¼0.54) with no evidence of a floor
effect. Patients in remission achieved lower HAQ scores than patients
with active disease and this effect was greater with increasing length
of remission. Patients in sustained remission achieved the lowest HAQ
scores (Table 1). This effect was persistent over time. Multivariate
logistic regression showed initial tender joint counts (OR 0.51, 95% CI
0.29 - 0.93) and ESR (OR 0.81, 95% CI 0.70 - 0.93) were the key
predictors of sustained remission.
Conclusions: Despite using GDT approach, only 10% of patients
achieved sustained remission. This was predicted by initial tender joint
count and ESR. Low HAQ scores are associated with remission, but
sustained remission is vital to minimise HAQ. As sustained remission
should be the ultimate treatment goal, the ideal treatment regime still
needs to be determined.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. Relationship between remission and HAQ over the consecutive visits.
Mean HAQ (S.D.)
Visit 1 Visit 2 Visit 3 Visit 4
Persistent Active disease 1.52 (0.70)* 1.52 (0.67)* 1.57 (0.06)* 1.52 (0.07)*
Point remission 1.07 (0.18)* 1.10 (0.10)* 1.17 (0.11)* 1.16 (0.10)*
Intermittent remission 0.85 (0.11)* 0.69 (0.10)* 0.74 (0.10)* 0.73 (0.10)*
Sustained remission 0.46 (0.09)* 0.42 (0.10)* 0.45 (0.14)* 0.45 (0.10)*
*ANOVA: p< 0.001 between different disease activity groups.
142. DO WE NEED SAME-DAY ESR FOR DAS-28
MEASUREMENT?
Sven Brode1, Muhammad K. Nisar2 and Andrew J. O¨sto¨r2
1School of Clinical Medicine, University of Cambridge, Cambridge,
United Kingdom; 2Rheumatology Clinical Research Unit,
Addenbrooke’s Hospital, Cambridge, United Kingdom
Background: The Disease Activity Score (DAS-28) is the most widely
used composite index of disease activity in Rheumatoid Arthritis (RA).
The components include the number of swollen and tender joints,
erythrocyte sedimentation rate (ESR) and visual analogue scale (VAS).
Serial measurements of the DAS-28 are strong predictors of physical
disability and radiological progression, and can sensitively discrimi-
nate between high and low disease activity. National Institute of Health
and Clinical Excellence recommends the use of DAS-28 to initiate and
monitor biologic therapy for RA. In clinical practice, rheumatologists
have been reluctant to calculate the DAS-28 without a same-day ESR
leading to unnecessary delay in adjusting targeted therapy. The aim of
this prospective study was to assess whether ESR blood samples
taken prior to the clinic appointment were adequate to accurately
assess disease activity using DAS-28.
Methods: Patients with RA (N¼130) attending rheumatology out-
patient clinics at Addenbrooke’s Hospital were selected and assessed
at baseline. Seventy three participants, mean age 61.8 years (range
20-85 yr) and disease duration of 12.0 years (range 0.1-40 yr)
completed the study. The tender and swollen joints were counted
and the global disease activity was assessed using a VAS. Blood
samples were collected for the ESR on the day of the appointment.
ESR results up to six months prior were obtained and used for
comparison.
Results: Comparing the same-day ESR versus pre-recorded ESR
(range 6-190 days, mean interval¼ 47 days) showed a statistically
significantly reduction in the same day ESR (K¼ 0.88 mm, CI95% 0.79-
1.07 mm, student t test, p<0.01). However, this small difference in
ESR did not significantly alter the DAS-28 score which remained
strongly linearly correlated. Changes in the ESR were not significantly
associated with the other clinical parameters used in the DAS-28 score
(p¼0.157). In addition, any differences between ESR pairs were not
correlated with the overall DAS-28 score. Time-dependent comparison
over a six month period showed a difference in DAS-28 of less
thanþ /- 0.6 using even up to three months old ESR results.
Conclusions: Our results indicate that in clinical practice changes in
DAS-28 due to an ‘‘out-of-date’’ ESR are minimal. The difference in
ESR values over a period of up to three months have no clinically
significant contribution to variations in DAS-28, especially in the
absence of any preceding changes in RA management. A decision to
adjust treatment may therefore be confidently made using latest ESR
for calculating DAS-28 even if ESR sample was not acquired during
clinic appointment.
Disclosure statement: The authors have declared no conflicts of
interest.
143. ACHIEVING REMISSION DURING GOAL DIRECTED
THERAPY IMPROVES FUNCTIONAL OUTCOME OF RA
IN ROUTINE PRACTICE
Nicola J. Gullick1,2, Stephen P. Oakley1,3, Jonathan D. Rees1,4,
Tim Jones1,4, Alan Mistlin1,4, Gabriel S. Panayi1,2 and
Bruce W. Kirkham1,2
1RA Centre, Rheumatology, Guy’s & St Thomas’ NHS Foundation
Trust, London, United Kingdom; 2NIHR comprehensive Biomedical
Research Centre, Guy’s & St Thomas’ Hospitals & King’s College
London, London, United Kingdom; 3Rheumatology, Royal Newcastle
Centre, Newcastle, NSW, Australia; 4Rheumatology, DMRC Headley
Court, Surrey, United Kingdom
Background: Recent EULAR guidelines recommend that RA patients
should be treated to a target of remission, but there is little data from
routine practice to suggest that this benefits patients. The RA Centre at
Guy’s & St Thomas’ has used this strategy aiming for DAS28 remission
for all patients with RA since 2005.
Methods: We performed a longitudinal cohort study involving all
patients attending the RA Centre. DAS28 and HAQ are collected at
each visit. Baseline and follow up at years 1, 2 and 3 have been
included in this analysis. All eligible patients were included in the
analysis. Comparisons were made between yearly timepoints. P
values less than 0.05 were considered statistically significant.
Results: 3 year follow up data were available for 281 patients, with
baseline visits occurring between 2005 and 2007. A variety of
therapies were used, with increasing numbers of patients receiving
biologic therapies during the follow up period, and reduced systemic
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steroids. Increasing numbers of patients achieved remission or low
disease activity during follow up with statistically significant improve-
ments in DAS28 at all time points vs. baseline (Table 1). For the whole
group, there was no significant change in HAQ. Of the 228 patients
with active disease (DAS282.6) at baseline, 119 achieved remission
at least once during follow up. These patients had a small but
significant improvement in HAQ from baseline to year 3 (median 1.25
vs. 1.0 p¼0.001). Patients in remission at baseline generally remained
in remission and had stable lower HAQ values over three years.
Conclusions: Routine use of the DAS28 to guide changes in therapy
improves disease activity and maintains functional capacity in an
unselected group of patients with established RA. In addition, patients
who achieve remission for even short periods had improved function.
This data supports the use of a goal directed strategy with a target of
DAS28 remission for patients with established RA in routine practice.
Achieving low DAS28 states is a relevant goal to prevent functional
decline. We suggest that increasing loss of function is another
significant adverse outcome of patients with even moderate disease
activity, and supports the use of more aggressive therapy in this group.
Disclosure statement:, B.K. has served on advisory boards for Pfizer,
Bristol-Myers Squibb, Centocor, Roche, UCB and Abbott, and has
received research grants from Pfizer, Centocor and Abbott. S.O. has
received a research grant from Sanofi-Aventis. All other authors have
declared no conflicts of interest.
TABLE 1. Follow-up clinical data
Baseline Year 1 Year 2 Year 3
DAS28, median (IQR) 4.0 (1.3) 3.3 (2)\$ 3.2 (2.1)j 3.1 (2.2)j
Activity
Remission n (%) 64 (22.8) 82 (29.2)j 89 (31.7)\$ 90 (32)j
LDAS n (%) 35 (12.5) 51 (18.1) 50 (17.8) 55 (19.6)
low MDAS n (%) 47 (16.7) 56 (19.9) 40 (21.7) 43 (18.5)
high MDAS n (%) 77 (27.4) 50 (17.8) 47 (16.7) 46 (16.4)
HDAS n (%) 58 (20.6) 47 (16.7) 40 (13.9) 43 (15.3)
Patient global score,
mean (S.D.)
41.8 (27.4) 39.4 (27.3) 36.1 (25.8) 36.8 (25.4)
Pain VAS, mean (S.D.) 40.6 (27.9) 38.5 (27.4) 36.3 (24.6) 38.6 (26.3)
ESR, mean (S.D.) 25.6 (21.8) 24.2 (19.6) 22.0 (18.6)* 19.6 (16.7)j
HAQ, median (IQR) 1.35 (0.9) 1.32 (0.9) 1.27 (0.8) 1.25 (0.9)
*p<0.05, \$ p< 0.01 j p< 0.001
144. INFLIXIMAB INFUSION THERAPY IN INFLAMMATORY
ARTHRITIS: ASSESSMENT OF THE ACCELERATED
INFUSION PROTOCOL IN COMPARISON TO THE
STANDARD INFUSION APPROACH
Yasser El Miedany1 and Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom
Background: Objectives: To assess the safety and prevalence of
infusion reactions in patients suffering from inflammatory arthritis
receiving infliximab via an accelerated infusion protocol in comparison
to the standard infliximab infusions (over 2-hour period). Also to
identify factors that may increase risk of an infusion reaction.
Methods: This was a retrospective study examining patients with
inflammatory arthritis receiving infliximab via the accelerated infusion
protocol (first four infusions over 2 h, with 2 h of monitoring, the next
five infusions over 1 h, and subsequent infusions over 30-60 min) in
comparison to the standard infliximab infusions administered over
minimum of 2 hours and patients are monitored for a further 2 hours.
Patients’ notes and prescription sheets were reviewed. Number
of patients who had to stop infliximab infusions due to allergic
reactions was recorded. Also the consumption of hydrocortisone and
anti-histamine injections was recorded. Disease characteristics includ-
ing rheumatoid factor and ANA were recorded in both groups and
compared.
Results: 112 patients received the accelerated protocol in comparison
to 139 patients treated using the standard infusion protocol. There was
a significant increase in infusion related reactions in the accelerated
infusions group 43/112 received anti-allergic therapy, in comparison to
29/139 in the second group (p<0.01). In the accelerated infusion
group 9/112 patients had to stop their infliximab infusions permanently
due to allergic reactions that could not be treated medically, in
comparison to none in the second group (p<0.001). The prevalence of
allergic reactions among the first group who received the accelerated
infusion protocol was, 16/43 had mild reaction, 24/43 had moderate
reactions and 3/43 had delayed hypersensitivity. In contrast, in the
standard infusion patients group 18/29 had mild reactions whereas 11/
29 had moderate reactions. No body in the standard infusion group
developed delayed hypersensitivity reactions (p<0.01) No differences
in disease characteristics or serology were associated with the
development of an infusion reaction. There was no significant
difference in adverse effects between patients receiving one or several
infusions.
Conclusions: There was a significant increase in the prevalence of
allergic reactions and use of anti-allergic injection therapy in the
patients who received the fast infliximab infusions. The prevalence of
allergic reactions among the standard infusion group agrees with the
data published earlier about the safety of infliximab infusion therapy.
Infusion allergic reaction varied in symptoms and duration, however, it
was not related to the number of infusions the patient might have. This
leaves every patient prone to allergic reactions at any time. Speeding
the infusion therapy was the main factor that may increase risk of an
infusion reaction.
Disclosure statement: The authors have declared no conflicts of
interest.
145. RENAL INVOLMENT IN RHEUMATOID ARTHRITIS AND
JUVENILE IDIOPATHIC ARTHRITIS
Ramanathan Porkodi1 and Panchapakesa Rajendran1
1Rheumatology, Madras Medical College, Chennai, India
Background: Haematuria and proteinuria in RA, JIA can occur
independent of drugs or urological disorders. This can be due to a
primary lesion associated with RA or due to amyloidosis. This study
was conducted to assess the renal involvement in RA and JIA.
Methods: During the period 1997-2010, patients with RA and JIA who
had symptoms of renal involvement, such as oliguria, haematuria, leg
oedema were included in the study.
Details of drug therapy were noted. Urine analysis, 24 hours urinary
protein, urea, creatinine, RF, ANA, C3, C4 levels, USG abdomen were
done. Renal biopsy for light microscope and immunofluroscence
studies was done by a nephrologist.
Results: 12 patients with RA, 4 patients with JIA had renal invlement.
The rheumatoid group consisted of 11 females and 1 male; while all
the JIA patients were males. 3 JIA patients had systemic onset, one
had polyarticular RF negative onset. Mean age at the time of inclusion
in the study was 39.33 years (range 22-58 years) for RA and 19.75
years (range 17-25years) for JIA patients. Mean duration of arthritis
before the onset of renal involvement was 6.52 years (3 months-15
years) in RA and 11.25 years (7-15 years) in JIA.
Renal biopsy in RA patients showed membranous nephropathy in
5 (41.66%) diffuse mesangial proliferation in 4 (33.33%), IgA nephro-
pathy in 2 (16.66%), crescentic glomerulo nephritis in 1 (8.33%). In
JIA 1 patient had membranous nephropathy (25%), 3 had amylodosis
(75 %).
In RA: Membranous Nephropathy in 5 females. One had been on
d.pencillamine, stopped 3 years before renal involvement. All had
nephrotic proteinuria, no haematuria, 2 had hypertension. Diffuse
mesangial proliferation in 3 females, 1 male. 2 patients had been on
d.pencillamine, stopped 2 and 3 years respectively before renal
involvement. One had hypertension,3 had nephrotic proteinuria, 1 non-
nephrotic proteinuria, 3 had microscopic haematuria. IgA nephropathy
in 2 females. One was on parenteral gold, stopped 3 years before renal
involvement. Both had non-nephrotic proteinuria, one had macro
haematuria, one micro haematuria. Crescentic glomerulo nephritis in
one female patient who presented with oliguria, macro haematuria, no
nephrotic proteinuria, elevated urea and creatinine.
In JIA Amyloidosis: 3 systemic onset JIA had nephrotic proteinuria.
Membranous Nephropathy: One JIA patient with polyarticular RF
negative onset had nephrotic proteinuria.
Conclusions: Membranous nephropathy was the commonest lesion
in RA followed by diffuse mesangial proliferation and IgA nephropathy.
Crescentic glomerulo nephritis occurred in one patient. In JIA amylo-
idosis was the most common lesion while one patient had membra-
nous nephropathy. These lesions seemed to be independent of drug
therpy and should be due to chronic inflammation of the rheumatoid
disease itself.
Disclosure statement: The authors have declared no conflicts of
interest.
146. THE SWINDON RA FOOT AND ANKLE QUESTIONNAIRE:
IS A PICTURE WORTH A THOUSAND WORDS?
Rosemary Waller1, Lyn Williamson1, David Collins1, Elizabeth Price1
and Maria J. Juarez1
1Rheumatology, Great Western Hospital, Swindon, United Kingdom
Background: Despite increased awareness of the high prevalence
and significance of foot and ankle problems in Rheumatoid Arthritis
(RA), feet remain a neglected area and provision of care a ‘Cinderella’
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service in many NHS Trusts. Reasons may include the perception that
feet are difficult to assess and foot and ankle is not included in the
standard DAS28 score. Currently available tools screening for foot
problems are either not freely available, not specific for RA or are
lengthy to complete.
Methods: We designed a short, simply worded questionnaire to
screen for foot and ankle problems in rheumatology outpatients. Key
features are 10 short questions on 1 side of A4 covering the domains
of symptoms, function, disability and previous intervention. The unique
feature of the questionnaire is the inclusion of pictures of dorsal,
plantar and lateral views of both feet. The questionnaire was piloted
and modified after an anonymous survey of 448 patients at our
institution in December 2009. All RA patients on our database were
sent the questionnaire and invited to attend clinic for a detailed foot
and ankle assessment. Each question was answered yes or no: yes
score 1; no score 0; maximum score 10. Patients assessed in clinic
were scored out of 10 using the same parameters as the ques-
tionnaire. The picture was reviewed at the end of the consultation and
scored as ‘accurate’, ‘not accurate’ or ‘not completed’. Any interven-
tion (including injection, orthotics or surgical review) arranged as a
result of the clinic was documented.
Results: 597 questionnaires were sent, 301 returned and 137 patients
were seen in clinic; 69% female; median age 62; mean RA duration 14
years (range 1 - 40 years). There was good correlation between the
postal questionnaire score, the score assigned at clinic (r¼ 0.63) and
the Manchester foot score (MFS) (r¼0.65). Neither score correlated
with other disease outcome measures used to assess RA, including
DAS28, Health Assessment Questionnaire, Overall Status in
Rheumatoid Arthritis & Hospital Anxiety & Depression scores.
96 (75%) patients completed the picture. Those who did had higher
scores and 73% corresponded well to clinical findings. 124 (91%)
patients had at least one foot or ankle problem: MTP synovitis (17%);
peroneal and tibialis posterior tendonopathies (22%); hallux valgus
(38%) and callosities (18%) were the most common. 45% of patients
received an intervention as a result of their clinic review. Those
requiring intervention had a trend towards a higher score.
Conclusions: The Swindon RA Foot and Ankle Questionnaire was
quick to complete, did not add to consultation length and correlated
well with the MFS. Lack of association with other standard RA
outcome measures suggests that relying on measures such as DAS28
alone may miss clinically important foot pathology. The picture was a
useful complement to the questionnaire. This simple screening tool
used regularly in clinic could aid early identification and treatment of
RA foot and ankle problems.
Disclosure statement: The authors have declared no conflicts of
interest.
147. TOWARD UNIFYING FUNCTIONAL DISABILITY
MEASUREMENT: INTERCONVERSION OF HAQ AND THE
COMBINED INFLAMMATORY ARTHRITIS QUESTIONNAIRE
FOR FUNCTIONAL DISABILITY SCALES
Yasser El Miedany1,2, Maha El Gaafary3, sally Youssef1,2 and
Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom;
2Rheumatology and Rehabilitation, Ain Shams University, Cairo,
Egypt; 3Community, Environmental and Occupational Medicine,
Ain Shams University, Cairo, Egypt
Background: The combined inflammatory arthritis questionnaire for
functional disability (CIAQ-Fn) and quality of life was recently published
[1] and included as part of the multidimensional PROM questionnaire
[2]. In comparison to the standard HAQ, the new questionnaire
for functional disability includes 10-items scale that is easier than
the HAQ to use and score. However, HAQ remains the standard and
most common questionnaire to be used in standard practice.
Objective: To compare: 1. the ability of the HAQ and CIAQ-Fn
disability questionnaires to perform in standard clinical practical
setting, 2. the Change in HAQ and CIAQ-Fn disability scores over
time and 3. the possibility of interconversion of HAQ and CIAQ-Fn.
disability scales.
Methods: 562 RA patients who received DMARD(s) therapy for their
inflammatory arthritis over 6-months period were included in this work.
The HAQ and CIAQ-Fn questionnaires were completed simultaneously
by every patient whilst waiting for their assessment in the rheumatol-
ogy clinic once at baseline before starting their DMARDs therapy and
the other time was after 6-months of treatment. The comprehensibility
of both questionnaires was assessed using VAS (0-100). The ability of
the HAQ and CIAQ-Fn to perform in a standard clinical practice setting
over a 6-month period was compared. Linear regression for prediction
of HAQ from CIAQ-Fn disability has been carried out too.
Results: At the start of therapy, the scales were so closely allied and
have mean scores that differed by only 0.02 units (HAQ score was
(1.50) and the CIAQ-Fn score was (1.52). There was no significant
difference on assessment of the comprehensibility of both ques-
tionnaires (p> 0.05). Effect sizes were calculated for the before-after
difference for the HAQ and CIAQ-Fn. The effect size for the CIAQ-Fn
was 23.9 (95% confidence interval [95% CI] 19.4-28.4). The effect size
for the HAQ was 24.8 (95% CI 20.5-29.1). These differences were not
significant (P<0.216). Linear regression described the relationship
between variables by the regression intercept and coefficient. For the
current study, the intercept was ranging between 0.05 and 0.17 and
the regression coefficient was 0.98 with a standard error of 0.01.
Based on the linear regression for prediction: Y (CIAQ)¼ 0.172þ 0.912
(X) HAQ.
Conclusions: Assessment of HAQ and CIAQ-Fn disability in the
standard clinical practice revealed that both questionnaires are
applicable and that it is relatively easy to substitute one scale for the
other. The large sample size of this work as well as the strong
relationship between the HAQ and the CIAQ-Fn provide assurance of
the accuracy and reliability of the process of score inter-conversion
from the HAQ to the CIAQ-Fn and from the CIAQ-Fn to the HAQ.
Disclosure statement: The authors have declared no conflicts of
interest.
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148. A CONTROLLED PILOT ASSESSMENT OF THE UTILITY
OF VISUAL FEEDBACK IN THE TREATMENT OF EARLY
RHEUMATOID ARTHRITIS
Yasser El Miedany1,2, Maha El Gaafary3 and Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom;
2Rheumatology and Rehabilitation, Ain Shams University, Cairo,
Egypt; 3Community, Environmental and Occupational Medicine,
Ain Shams University, Cairo, Egypt
Background: Visual feedback has contributed in the management of
neuromuscular and psychiatric disorders, however, it has not yet been
applied in rheumatology. Visual feedback is a relatively new tool that
enables the patients to visualize and monitor a real-time change of
their disease activity parameters as well as the patient’s reported out-
come measures. Integrating electronic data recording in the standard
rheumatology clinical practice made visual feedback possible.
Objective: To evaluate the feasibility of using the visual feedback in
patients with early inflammatory arthritis (EA) and how ubiquitous
computing technology can improve the patients’ compliance and
adherence to therapy.
Methods: This was a double-blind randomized controlled study, which
included 111 patients diagnosed to have EA according to the new
ACR/EULAR criteria. All patients received DMARDs therapy and were
monitored over the period of 1-year. By the 6th month of treatment, the
patients were randomly allocated to an active group (55 patients) to
who the visual feedback (visualization of the charts showing the
disease progression) was added to their management protocol, and a
control group (56 patients) who continued their routine management.
The patients were monitored for another 6-months period. All the
patient’s disease activity parameters, patient reported outcome
measures (PROMs), medications and co-morbidity scores were
recorded using the EROMIA software [1]. Primary outcome was the
patients’ adherence to their medications; change in disease activity
score (DAS-28) and PROMs. Secondary outcome was the outcome of
a questionnaire completed by every patient in both the active group
and control group (using VAS) by the end of 1-year of management, to
rate the patient’s perspective regarding their condition and treatment.
Results: The visual feedback provided a significant reduction of
disease activity parameters as well as improvement of the patients’
adherence to anti-rheumatic therapy (p< 0.01). Also stopping the
DMARDs therapy because of intolerance was significantly less in the
active group. The improvement of disease activity parameters was
associated with improvement in functional disability and quality of life
scores. Mean changes in disease parameters showed no significant
differences at 3 and 6 months of therapy but differences were
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statistically significant at 12 months follow up (p<0.01). Medication
compliance was significantly correlated with changes in all measured
disease parameters
Conclusions: By recording and monitoring disease activity electro-
nically and introducting visual feedback therapy into clinical practice, a
new experience can be created. Visual feedback enabled the patients
to see how they are doing regarding their disease activity and helped
to optimize their adherence to their treatment. Visual feedback had a
positive and significant impact on the disease activity control.
Disclosure statement: The authors have declared no conflicts of
interest.
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149. SIX-YEAR OUTCOME OF EARLY ARTHRITIS CLINIC:
IMPLEMENTATION OF THE MATRIX MODEL FOR THE
PREDICTION OF RAPID RADIOGRAPHIC PROGRESSION
AND COMMENCING BIOLOGIC THERAPY
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2Community, Environmental and Occupational Medicine, Ain Shams
University, Cairo, Egypt
Background: The current paradigm for early arthritis suggests that the
inflammatory process is at its peak in the first few years, leading to
erosive joint damage and functional disability. Identifying patients with
RA at high risk of rapid radiographic progression (RRP) is critical for
making appropriate treatment decisions. The latest NICE guidelines
(2009) supported the recent trend of early diagnosis and management
of the condition. An early arthritis clinic has been set up at Darent
Valley Hospital, Dartford, for the past 6 years. Aim: To assess the
feasibility of implementing the visual matrix model, which would
predict the 1-year risk of rapid radiographic progression, for individual
patients diagnosed and managed in the early arthritis clinic. Also to
assess the ability of the matrix model to identify patients who might
need combination of DMARDs /commencing biologic therapy.
Methods: This was a case-control retrospective study. The matrix
model was applied to 102 patients who were diagnosed to have RA
according to the new ACR/EULAR criteria and treated according to
NICE guidelines (2009) (Mean time to start biologic therapy was
6.4þ0.52 months). The control group included 105 patients diag-
nosed to have early inflammatory arthritis in the period of 2005-2008
(Mean time to start biologic therapy was 14.3þ 1.8 months). The
matrix model was applied at 0 time (before starting DMARDs therapy),
3, 6 and 12 months after starting treatment. Biologic therapy was
commenced in group 1 by 6-months time of DMARDs therapy,
whereas the patients in group 2 continued on DMARDs therapy for the
whole of first year. Modified Sharp/van der Heijde score (SHS) was
assessed for all patients by the end of the first year of treatment.
Coordinates were illustrated to identify the best discriminating point
that shows the highest sensitivity and the lowest 1-specificity (false
positives) values.
Results: There was no significant difference on comparing the
baseline characteristics in both groups included in this work. By the
end of 1-year of therapy, there was significant difference (p< 0.001)
between the matrix score in both groups assessed (being significantly
lower in group 1) supporting the favorable effect of the biologic over
DMARDs therapy. Also, the matrix score correlated significantly with
the SHS score. AUC and coordinate points showed that the sensitivity
as well as specificity of the matrix score were highest at baseline, as
well as at 6-months of therapy followed by at 3 months of therapy.
Conclusions: The matrix models predicted the risk of RRP at 1-year
using initiated treatment and easily accessible clinical and laboratory
variables. The matrix model can be implemented in the early arthritis
clinic to identify those patients at risk who should receive the
combination of DMARDs therapy by 3-months or should start biologic
therapy by 6-months of starting DMARDs therapy.
Disclosure statement: The authors have declared no conflicts of
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150. IN THE AGE OF BIOLOGIC THERAPY: WHICH ANTI-TNF
AGENT IS SAFE TO USE IN PATIENTS WITH LATENT
TUBERCULOSIS
Yasser El Miedany1 and Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom
Background: The failure to screen for tuberculosis before the initiation
of biologic therapy may result in adverse outcomes for both the patient
and the overall health of the community. Similarly, reactivation of latent
tuberculosis (patients infected with M. tuberculosis but does not have
active tuberculosis disease) is a high risk in inflammatory arthritis
patients treated with anti-TNF therapy, as this may lead to activation of
the infection. Antigen-specific -IFN release assays such as T-SPOT
have been evaluated in various populations and are reported to
perform better than tuberculin skin testing in the diagnosis of TB
infection (high specificity (93-99%).
Aim: to assess the safety of the different anti-TNF agents in patients
with latent tuberculosis and the impact of anti-tuberculous therapy on
the disease activity.
Methods: Upon referral for biologic therapy, all patients were
assessed in the pre-biologic therapy assessment clinic. Assessment
of tuberculosis infection risk includes history of specific symptoms
(productive cough of stained sputum or TB travel risk factors for
individual or close relatives), BCG scar, chest X-ray and T-spot test. 21
patients with latent TB were identified and treated with antituberculos
agent under care of the chest clinic for 3 months following which anti-
TNF therapy was started. Patient choice approach was implemented,
after explaining all pros and cons of different anti-TNF agents
available. Patients were monitored 3 monthly for symptoms of active
TB disease, disease activity and compliance to their medications.
Chest x-ray was taken every 3 months. Primary outcome was the
chest status at the end of the year and whether there has been flare up
of the TB infection. Secondary outcome was the disease activity score
at the end of the year.
Results: 8 patients received enbrel, 7 patients received humira
whereas 6 patients received infliximab infusions. There was no
significant difference on comparing, age, sex or disease activity
parameters between the 3 groups (p>0.05). Prior to therapy, chest x-
ray did not show any active lung lesion in all patients presented with
reactive T-spot test. At one year of anti-TNF therapy there was no
activation of TB infection in any patient in the 3 groups. There was no
significant difference between the 3 patients groups in terms of
disease activity parameters (p>0.05).
Conclusions: It is relatively safe to use any of the anti-TNF agents,
enbrel, humira, or infliximab in patients with latent TB. Having a
reactive T-spot test/ latent tuberculosis is not a contraindication to
anti-TNF therapy. Using anti-tuberculous therapy for 3 months after
which the patient can start his anti-TNF therapy with 3 monthly X-ray
chest seems a safe protocol for this group of patient.
Disclosure statement: The authors have declared no conflicts of
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151. SYSTEMATIC REVIEW AND META-ANALYSES OF
NON-PHARMACOLOGICAL INTERVENTIONS FOR FATIGUE
IN RHEUMATOID ARTHRITIS
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Ernest Choy3, Trudie Chalder4, Jon Pollock1 and Robin Christensen5
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Parker Institute: Musculoskeletal Statistics Unit (MSU), Copenhagen
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Background: Fatigue is a common and distressing symptom for
patients with rheumatoid arthritis (RA) with no accepted evidence
based management guidelines. Non-pharmacological interventions,
such as physical activity and psychosocial interventions have been
shown to help people with a range of other long term conditions
manage subjective fatigue. The objective of this review was to evaluate
the effectiveness and safety of non-pharmacological interventions for
the management of fatigue in people with RA.
Methods: The following electronic databases were searched:
Cochrane Central Register of Controlled Trials; Cochrane Database
of Systematic Reviews; Current Controlled Trials Register; The
National Research Register Archive; The UKCRN Portfolio Database;
MEDLINE; EMBASE; AMED; CINAHL; PsycINFO; Social Science
Citation Index; Web of Science; Dissertation Abstracts International.
In addition reference lists of articles identified for inclusion were
checked for additional studies and key authors were contacted.
Randomised controlled trials were included if they evaluated a
non-pharmacological intervention in people with RA, with self-reported
fatigue as an outcome measure. Two reviewers selected relevant
trials, assessed methodological quality and extracted data. The
Standardized Mean Difference (SMD) was applied as the effect
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measure applicable across different outcome measures. Data were
pooled using meta-analysis with a random-effects model with
inconsistency evaluated based on the I-squared value.
Results: Of 54 studies initially identified, 19 met the inclusion criteria
with a total of 2240 participants with RA. Included studies investigated
physical activity interventions (k¼ 5), psychosocial interventions
(k¼10), herbal medicine (k¼ 1), omega-3 fatty acid supplementation
(k¼1), Mediterranean diet (k¼1) and the provision of Health Tracker
information (k¼1). The risk of bias in the included studies varied from
high (53%) to low (37%). No adverse effects were reported in any of
the studies. Only three studies reported adverse events but there was
no clear difference in incidence or severity between the intervention
and control groups. At the end of the intervention period a non-
significant trend in favour of physical activity was demonstrated for
pre-post test mean change in self-reported fatigue (SMD -0.17, 95%
CIs -0.53 to 0.18; I-sq¼56%). A non-significant trend in favour of
psychosocial interventions was also demonstrated (SMD -0.14, 95%
CIs -0.30 to 0.02, I-sq¼ 19%). The remaining four studies investigated
diverse non-pharmacological interventions and were therefore not
appropriate for combining within a meta-analysis.
Conclusions: This systematic review shows that there is currently
insufficient evidence of the effectiveness of non-pharmacological
interventions in the management of self-reported fatigue in RA
patients. Psychosocial interventions and physical activity show some
promise but require further investigation.
Disclosure statement: S.H. has received research grants from
GlaxoSmithKline and Arthritis Research UK. All other authors have
declared no conflicts of interest.
152. FACTORS ASSOCIATED WITH EXCESS
ATHEROSCLEROTIC PLAQUE IN EARLY INFLAMMATORY
POLYARTHRITIS: RESULTS FROM THE NORFOLK
ARTHRITIS REGISTER
Hoda Mirjafari1, Suzanne Verstappen1, Diane Bunn2, Helena Edlin3,
Valentine Charlton-Menys4, Philip Pemberton5, Tarnya Marshall2,
Paddy Wilson2, Mark Lunt1, Deborah Symmons1 and Ian N. Bruce1
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, United Kingdom; 2Rheumatology Department, Norfolk
and Norwich University Hospitals, Norwich, United Kingdom;
3Department for Vacular Studies, Manchester Royal Infirmary,
Manchester, United Kingdom; 4Cardiovascular Research Group,
The University of Manchester, Manchester, United Kingdom;
5Biochemistry Laboratory, Manchester Royal Infirmary, Manchester,
United Kingdom
Background: Patients with inflammatory polyarthritis (IP) have excess
cardiovascular (CVD) mortality due to accelerated atherosclerosis.
Identifying individuals with subclinical atheromatous plaque and
markers associated with it may allow for targeted CVD risk manage-
ment early in disease. We aimed to compare the prevalence of carotid
atherosclerosis in early IP and controls and to identify risk factors
associated with this in early IP.
Methods: Consecutive patients with early IP ( 2 joints swollen for 4
weeks) aged 18-65 years, who were within 24 months of symptom
onset were recruited as part of a primary-care based inception cohort
between 2004-2008. Patients were age and gender frequency
matched with controls. At baseline, subjects had classic risk factors
assessed, underwent joint examination, had blood taken to assess
serological status, the acute phase response as well as paroxonase
1 (PON1) apolipoprotein (Apo) A1 and B, markers of endothelial
activation (E-selectin, vascular cell adhesion molecule (VCAM)) and
adipocytokines (leptin and adiponectin). All subjects had a B mode
Doppler ultrasound examination of the carotid arteries for the presence
of plaque. In univariate logistic analyses we identified factors that were
associated with plaque after age and gender adjustment. An additive
stepwise multivariable regression model was developed to investigate
independent associations with plaque.
Results: Of the 329 patients and 67 controls studied 96 (29%) and 26
(33%) were male respectively. In patients the median (IQR) age and
symptom duration at study entry were 51 (42-58) years and 6.6 (4.2-
11.2) months. 14 (4%) patients had prior CVD. Patients were more
likely to smoke (75 [23%] vs 3 [4%] p<0.05), be on antihypertensives
(42 [13%] vs. 2 [2%] p< 0.05) and have previous steroid exposure
(62 [19%] vs. 2 [3%] p<0.05). Carotid plaque was more prevalent in
patients than controls on baseline scans (151[46%] vs 16 [24%] OR
[(95% CI] 2.9 [1.6, 5.2]). In univariate analysis; age, smoking, BP, total
cholesterol, LDL, triglyceride, hs-CRP, adiponectin and Apo B were
significantly associated with plaque in patients. In an additive stepwise
multivariable regression model age, BP, Apo B, and adiponectin
remained independent predictors of plaque (Table 1).
Conclusions: Carotid plaque is more prevalent in IP patients from
early in the disease course and is driven principally by traditional risk
factors.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. Cardiovascular, IP and novel risk factors associated with plaque in IP
subjects at baseline.
Variable IP Subjects Odds Ratio (95% CI)
Age when seen (per year) 1.10 (1.06, 1.14)
Apo B (per g/L) 211.47 (8.73, 5123.04)
Adiponectin (per mg/L) 1.17 (1.04, 1.31)
Systolic BP (per mmHg) 1.02 (1.00, 1.04)
Logistic regression producing ORs used for binary outcomes. ORs are considered
significant if the 95% CIs do not include 1. Adjustments were made for age
and gender.
153. THE RECOGNITION AND ASSESSMENT OF
CARDIOVASCULAR RISK IN PEOPLE WITH RHEUMATOID
ARTHRITIS IN PRIMARY CARE: A QUESTIONNAIRE-BASED
STUDY OF GENERAL PRACTITIONERS
Carolyn Bell1 and Ian F. Rowe1
1Rheumatology, Worcestershire Acute NHS Trust, Worcester,
United Kingdom
Background: Rheumatoid arthritis (RA) is a chronic, inflammatory
disease affecting approximately 1% of the adult population. Patients
with RA are recognised as having increased cardiovascular morbidity
and mortality. Within the UK the majority of cardiovascular risk
assessment and management occurs within primary care. This study
aimed to determine how well recognised the association between RA
and excess cardiovascular risk is within primary care and the current
assessment strategies being employed by general practitioners (GPs).
Methods: Questionnaires were sent to all 376 GPs in the
Worcestershire Primary Care Trust.
Results: : Of the 207 GPs responding to the questionnaire 32%
identified RA as an independent risk factor for cardiovascular (CV)
disease. 15% and 34% respectively assessed their RA patients for
primary and secondary prevention of their CV risks. Of those who
made an assessment 18.4% of GPs adjusted the calculated risk
derived from standard charts. The frequency of assessment was
statistically significantly greater (p¼< 0.0001) among those GPs who
had received a form of education about the association between CV
disease and RA. However of the GPs identifying this susceptibility only
40% performed any form of primary prevention risk assessment. 5.3%
of GPs felt that CV risk management should occur in secondary care
with 84% and 85% respectively reporting that a review article or
presentation about cardiovascular risk in RA would be useful to their
daily practice.
Conclusions: At present the excess risk of CV disease conferred by
RA is under-recognised and under-assessed in primary care. Currently
educational resources on this topic targeted at GPs are lacking and
may in part account for our findings. However, even when GPs did
identify the risk of CV disease in RA or had received education about it,
this did not consistently change their clinical management. Further
work to promote knowledge and management strategies for CV
disease in RA is therefore needed to improve the care of patients with
this condition.
Disclosure statement: C.B. has received sponsorship to attend a
conference from Roche. All other authors have declared no conflicts of
interest.
154. SUSTAINED CLINICAL REMISSION IN RA:
PREVALENCE AND PROGNOSTIC FACTORS IN AN
INCEPTION COHORT OF PATIENTS TREATED WITH
CONVENTIONAL DMARD THERAPY
Keeranur Jayakumar1, Sam J. Norton2, Josh Dixey1, Peter Williams1
and Adam Young1
1Rheumatology, ERAS, St Albans, United Kingdom; 2Centre for
Lifespan & Chronic Illness Research, University of Hertfordshire,
Hatfield, United Kingdom
Background: Clinical remission is now a realistic goal in managing
rheumatoid arthritis (RA) since the introduction of biologics. However,
data on sustained clinical remission in conventionally treated RA is
limited. This study examines prevalence/predictive factors of sus-
tained clinical remission in patients treated with standard DMARD
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therapy prior to the biologic era in an inception cohort over the first 5
years.
Methods: Consecutive newly diagnosed RA patients (<2yrs from
symptom onset and DMARD naı¨ve) were recruited at presentation
from 9 centres across England into an inception cohort (1986-1998)
(n¼ 1460), and followed annually employing standard clinical, labora-
tory and radiological assessments. Disease activity was assessed
using the original 3-variable DAS that uses swollen/tender joint counts,
and acute phase response (ESR/CRP). Point remission (DAS at one
point) was defined by DAS< 1.6 according to EULAR response criteria
(DAS28<2.6). For this study, sustained clinical remission was defined
by DAS<1.6 at all 3, 4 and 5yr follow ups, non remission if DAS>¼1.6
at all 3 follow ups, and partial remission for other combinations.
Outcomes included structural damage (Larsen scores of hand/foot X-
rays) and functional ability (HAQ). Odds ratios (OR) with 95%
confidence intervals (95%CI) were calculated to examine the strength
of predictive factors for clinical remission. 704 patients had minimum
5yrs follow-up with DAS recorded at baseline, 3rd, 4th and 5th yr
follow-ups, and were included in the analysis. Monotherapy was used
in 43%, sequential monotherapy 30%, combination therapy 18%, the
remainder 9% steroidal/non-steroidal drugs only.
Results: Point remission based on DAS at 3, 4 and 5yrs was 25%,
26% and 22% respectively, but only 11% (n¼78) had sustained DAS
remission. Baseline predictors for sustained DAS remission using
univariate analysis were men (OR 2.6, 95%CI 1.6-4.2), 6 or less months
of symptoms prior to study entry (OR 1.6, 95%CI 1.0-2.7), <10 tender
joints (OR 3.0, 95%CI 1.7-5.0), <13 swollen joints (OR 1.9, 95%CI 1.1-
3.0), DAS < 4.1 (OR 2.7, 95%CI 1.6-4.6) and HAQ <1.0 (OR 2.1,
95%CI 1.3-3.6). Only men, symptom duration and tender joints
remained independent predictors of sustained DAS remission in
multivariate analysis. Patients with sustained DAS remission by 5yrs
had better outcomes over time as assessed by less DMARD therapies,
radiographic progression and functional impairment. Mean HAQ
decreased from 0.17-0.13 (p<0.001) in sustained DAS remission,
compared to an increase from 0.92-1.1 (p<0.001) in the non-
remission group.
Conclusions: In RA patients managed with conventional DMARDs,
point remission rates were around 25%. 11% had sustained DAS
remission by 5yrs with a positive impact on structural/functional
outcomes. These results provide a benchmark for modern pharma-
cological approach to RA. Remission maintenance, not only induction
should be the main therapeutic target.
Disclosure statement: The authors have declared no conflicts of
interest.
155. THE SAFETY AND ACCEPTABILITY OF
ULTRASOUND-GUIDED BIOPSY IN EARLY ARTHRITIS
PATIENTS
Hariney Kurunadalingam1, Iram Parwaiz1, Kanta Kumar1,
Kath Howlett1, Becki Hands2, Karim Raza1, Costantino Pitzalis2,
Chris Buckley1, Stephen Kelly2 and Andrew Filer1
1Rheumatology Research Group, University of Birmingham,
Birmingham, United Kingdom; 2Rheumatology Department, Barts
and the Royal London, London, United Kingdom
Background: Current research strategies addressing prediction of
outcome in early arthritis such as PEAC (the Pathobiology of Early
Arthritis Cohort) and the Birmingham Very Early Arthritis Clinic rely
upon the procurement of tissue from patients at the earliest stages of
disease, necessitating safe, minimally invasive techniques which are
acceptable to newly presenting arthritis patients. We assessed the
safety and acceptability of ultrasound guided biopsy, a less invasive
alternative to formal arthroscopy, used by centres in Birmingham and
London.
Methods: Patients with treatment naive early synovitis of at least one
joint, up to one year symptom duration, and at least one joint
amenable to synovial biopsy gave written informed consent to be
recruited from hospitals in London and Birmingham, representing the
first cohort of patients in the UK upon whom these procedures were
performed. The patients were assessed pre, intra and 2 weeks post
biopsy on a standard proforma. Patient reported information on joint
status and patient acceptability was recorded by likert scales, visual
analogue scales (VAS) and free text entry in a confidential proforma.
Results: 123 participants were included (mean age 53 (19-83) years,
M:F 53:70). Adverse events were compared with data for conventional
arthroscopy. During biopsy arthralgia occurred in 24%, while minor
complications of presyncope and syncope occurred below 3%, with
no DVT, joint infection, thrombophlebitis or neurovascular damage.
The only significant complication was a wound infection, used as
a critical event to inform further practice in the collaborative network.
A single, mild haemarthrosis occurred, giving a similar rate to major
haemarthrosis seen with conventional arthroscopy (0.8% vs 0.9%).
Patient acceptability of biopsy procedures was excellent. The majority
(81%) of biopsies involved either minimal or no discomfort. Biopsies of
small joints involved significantly less discomfort than large joints
(p<0.0001), but provided less tissue for analysis. Two weeks post
procedure, most patients (98% Birmingham, 91% London) felt the
biopsied joint was ‘‘the same’’ or ‘‘better’’. Significantly more patients
in Birmingham felt the joint was improved (p<0.05), due to a higher
number of very early patients with resolving arthritis. Corresponding
improvements in VAS scores for pain, swelling and stiffness were
seen. Crucially, most patients (81% in Birmingham and 72% in
London) would be likely to consent to a repeat procedure.
Conclusions: Acknowledging a single early wound infection, the side
effect profile of US guided biopsy matches or improves upon
conventional arthroscopy with an excellent acceptability profile.
Patients are happy to undergo repeat procedures (12 repeat biopsies
in the Birmingham cohort to date). This novel technique has the
potential to replace arthroscopy as a research and clinical trial
procedure.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
Joint PIP MCP Wrist Elbow Knee Ankle MTP
n 1 20 12 6 74 8 2
156. SUPPRESSION OF BONE TURNOVER
BY B-CELL DEPLETION IN PATIENTS WITH RHEUMATOID
ARTHRITIS
Gill Wheater1, Vanessa E. Hogan2, YK Onno Teng3,
Janneke Tekstra4, Stephen P. Tuck5, Floris P. Lafeber4,
Tom W. Huizinga3, Johannes W. Bijlsma4, Roger M. Francis2,
Harish K. Datta2 and Jaap van Laar2,5
1Biochemistry, The James Cook University Hospital, Middlesbrough,
United Kingdom; 2Musculoskeletal Research Group, Newcastle
University, Newcastle upon Tyne, United Kingdom; 3Rheumatology,
Leiden University Medical Centre, Leiden, Netherlands;
4Rheumatology and Clinical Immunology, University Medical Centre
Utrecht, Utrecht, Netherlands; 5Rheumatology, The James Cook
University Hospital, Middlesbrough, United Kingdom
Background: Recent investigations have provided abundant evidence
for an intricate interaction between the immune and skeletal systems.
Rheumatoid arthritis (RA) is the most prevalent inflammatory joint
disease, in which B cells play an important role. The skeletal
complications of RA consist of focal erosion of marginal and
subchondral bone, juxta-articular osteoporosis and generalised bone
loss with reduced bone mass. The role of B-cells in bone turnover is
controversial and RA subjects treated with rituximab therapy provide
an ideal model for determining the role of B cells in inflammatory bone
resorption. This study was undertaken to investigate changes in
biochemical markers of bone turnover before and after B cell depletion
therapy in RA patients.
Methods: Serum from 46 patients with refractory RA, collected pre-
and post-rituximab, was analysed for biomarkers of bone turnover
(procollagen type 1 amino-terminal propeptide [PINP], osteocalcin,
beta-isomerised carboxy terminal telopeptide of type I collagen
[bCTx], osteoprotegerin [OPG]).
Results: A significant decrease in bone resorption was observed 6
months after rituximab (median change bCTx -50 ng/L, 95%CI -8,-136,
p<0.001), mirrored by a significant reduction in disease activity. There
was a significant increase in PINP (median change 5.0 mg/L, 95%CI -
1.0, 11.2, p¼0.02), a marker of bone formation, but no significant
change in osteocalcin or OPG levels. The percentage change from
baseline of bCTx in a subgroup of patients (not on prednisolone or a
bisphosphonate) was significantly correlated with the percentage
reduction in DAS28 score (rs¼0.570, p¼0.014).
Conclusions: B-cell depletion with rituximab in RA results in a
significant suppression in bone resorption accompanied by an
increase in bone formation. This may be a direct effect on osteoblasts
and osteoclasts respectively, and be at least partially explained by the
decreased inflammation and disease activity.
Disclosure statement: J.B. and J.V. have received consultancy and
speaker fees and research grants from Roche. T.H. has received
lecture/consultancy fees from Schering-Plough, Bristol-Myers Squibb,
Biotest AG, Wyeth/Pfizer, Novartis, Roche, Sanofi-Aventis, Abbott and
Axis-Shield diagnostics, and support for travelling to EULAR/ACR
meetings from Roche and Abbott. S.T. has received speaker fees from
Eli Lilly. All other authors have declared no conflicts of interest.
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157. DOES TESTING FOR CIRCULATING AUTOANTIBODIES
AGAINST DISEASE-RELEVANT CITRULLINATED ANTIGENS
ADD VALUE TO THE CCP2 ASSAY IN DIAGNOSING RA
AMONG EARLY UNDIFFERENTIATED ARTHRITIS PATIENTS?
Arthur G. Pratt1, Peter J. Charles2, Muslima Choudhury2,
Gill Wilson1, Patrick J. Venables2 and John Isaacs1
1Institute of Cellular Medicine, Musculoskeletal Research Group,
Newcastle University, Newcastle-upon-Tyne, United Kingdom;
2The Kennedy Institute of Rheumatology, Imperial College, London,
United Kingdom
Background: The antigen substrates employed in the widely-used
CCP2 assay do not correspond to in vivo-generated citrullinated
proteins so far implicated in the pathogenesis of RA. We assessed the
diagnostic utility of circulating autoantibodies to a panel of such
peptides amongst UA patients, and whether permutations thereof
might improve upon the diagnostic utility of CCP2 testing alone.
Methods: UA patients presenting to the Newcastle Early Arthritis
Clinic who were naı¨ve to immunomodulatory treatment were recruited.
In addition to routine testing using the CCP2 assay, baseline sera were
tested for reactivity to citrullinated forms of fibrinogen (cFbg), vimentin
(cVim), cyclic alpha enolase peptides 1 and 11 (CEP-1 and CEP-11),
linear filaggrin (Fil-LC), and a panel of 6 citrullinated pro-filaggrin-
derived peptides. Corresponding native forms of the same peptides
were used as negative controls where possible, and testing for IgA and
IgM rheumatoid factor (RF) was also undertaken, with assay cut-offs
being determined based on healthy control populations. Clinicians
were blinded to all but the CCP2 results, and follow-up was for >1 year
(median 28 months) Individuals for whom definitive outcome diagnosis
was not reached within the study period were excluded from analysis.
The 1987 ACR classification criteria were used for the diagnosis of RA.
Results: Assays were carried out for 75 newly presenting UA patients,
of whom 29 (39%) developed RA.The specificity, sensitivity, positive
and negative predictive values (PPV and NPV) of CCP2 with respect to
an RA outcome in this cohort (95% confidence intervals) were 0.98
(0.87-1.0), 0.48 (0.30-0.67), 0.93 (0.66-1.0) and 0.75 (0.62-0.85)
respectively. No single assay evaluated displayed superior NPV over
CCP2 without compromising the PPV afforded by that test. Neither did
combinations of assays, considered in permutations with or without
CCP2, add value to CCP2-testing alone in predicting RA. Hierarchical
clustering of all assay profiles revealed cFbg reactivity to correlate
most closely with CCP2 test positivity amongst these sera (PPV and
NPV 0.80 [0.51-0.95] and 0.70 [0.56-0.81]) respectively. In general, IgM
RF positivity had a NPV equivalent to that of the CCP2 test, but an
inferior PPV (0.65 [0.44-0.82]), and, after the CCP test, the best assay
with regards PPV for RA was found to be CEP-1 (0.83 [0.36-0.99]).
Conclusions: The CCP2 test remains an invaluable diagnostic tool in
the assessment of UA because of its impressive PPV, but the
identification of biomarkers for the diagnosis of autoantibody negative
RA must remain a priority.
Disclosure statement: The authors have declared no conflicts of
interest.
158. DELAYS IN ASSESSMENT OF PATIENTS WITH NEW
ONSET RHEUMATOID ARTHRITIS: VARIATIONS ACROSS
EUROPE
Karim Raza1, Kanta Kumar1, Rebecca Stack1,
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Giorgio Tamborrini7, Diego Kyburz7, Hans Bastian8, Gerd
R. Burmester8, Jacqueline Detert8 and Christopher D. Buckley1
1Immunity and Infection, University of Birmingham, Birmingham,
United Kingdom; 2Rheumatology, Institute of Rheumatology,
Warsaw, Poland; 3Department of Rheumatology, University Hospital,
Umea, Sweden; 4Department of Clinical Sciences, Section of
Rheumatology, Lund University, Lund, Sweden; 5University of Crete,
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Charles University, Prague, Czech Republic; 7Department of
Rheumatology, University Hospital Zurich, Zurich, Switzerland;
8Department of Rheumatology and Clinical Immunology, Charite´,
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Background: The first 3 to 4 months after symptom onset represent
an important therapeutic window in RA. Delays in assessment by
rheumatologists, and consequently in DMARD initiation, reflect a
composite of 4 time intervals: [1] Onset of symptoms to request to see
health care professional (HCP); [2] Request to see HCP to assessment
by HCP; [3] Initial assessment by HCP to referral to rheumatologist; [4]
Referral to rheumatologist to assessment by rheumatologist. In
previous work from the UK, the median delay from symptom onset
to rheumatology assessment was over 20 weeks. We sought to
quantify delays in assessment of RA patients across Europe and to
identify the principal reasons for delay in different countries.
Methods: Data (the 4 levels of delay listed above, age, gender and the
initial HCP of contact) were collected from consecutively presenting
RA patients fulfilling 1987 ACR criteria at initial assessment in
Birmingham, Umea˚, Lund, Berlin, Warsaw, Prague, Zurich and Crete.
Results: Details of patients are shown (Table 1). The median delay
from onset of inflammatory joint symptoms to assessment by a
rheumatologist ranged from 20 to 38 weeks. The relative contributions
of each level of delay to the total delay varied between units. In
Birmingham and Crete, the greatest contribution was delay on the part
of the patient in consulting a HCP. In Umea˚, Lund, Prague and Zurich,
delay on the part of the patient in consulting a HCP, and delay on the
part of the HCP in referring to a rheumatologist were equivalent
contributors to overall delay. In Berlin and Warsaw, delay on the part of
the patient in seeking medical advice was relatively short, with other
components accounting for the majority of the overall delay.
Conclusions: Across Europe, delays in the assessment of RA patients
by rheumatologists are too long. Tackling this should represent an
important priority for strategies to improve RA outcomes. This study
highlights the levels of delay that need to be targeted in individual
countries.
TABLE 1.
Birmingham Umea Lund Berlin Warsaw Prague Zurich Crete
Number of patients 50 50 48 50 50 50 49 42
Age, median (IQR), years 55 (44-69) 55 (42-67) 58 (45-68) 44 (35-59) 55 (47-62) 56 (40-60) 53 (36-62) 53 (43-62)
Gender: female, number (%) 33 (66) 36 (72) 35 (73) 35 (70) 41 (82) 35 (70) 37 (76) 36 (86)
Initial health care professional (HCP) of contact
GP 49 47 46 26 36 35 46 2
Rheumatologist 0 0 0 2 7 4 0 12
Internist 0 0 0 2 3 1 1 9
Company health service 0 3 0 0 0 0 0 0
Orthopaedic surgeon 0 0 0 13 2 9 1 19
Emergency department 1 0 0 5 0 0 0 0
Neurologist 0 0 0 0 1 0 0 0
Not recorded / other 0 0 2 2 1 1 1 0
Delay 1: Patient delay in seeking appoint-
ment with initial HCP, median (IQR), weeks
12 (3-64) 8 (2-17) 8 (4-8) 2 (1-8) 4 (1-8) 8 (2-12) 8 (4-13) 22 (8-72)
Delay 2: Delay in assessment by initial HCP
once decision to seek advice made,
median (IQR), weeks
1 (<1-1) 1 (<1-2) 2 (1-2) 2 (1-4) 2 (1-8) <1 (<1-2) 1 (1-2) 12 (6-63)
Delay 3: Initial HCP delay in referral to
Rheumatologist, median (IQR), weeks
2 (1-5) 8 (2-20) 8 (4-12) 10 (3-23) 12 (2-48) 10 (3-52) 8 (4-15) 3 (0-4)
Delay 4: Rheumatologist delay in seeing
patient once referral made, median (IQR),
weeks
4 (2-6) 4 (2-5) 3 (2-4) 11 (4-14) 4 (1-8) 4 (2-8) 2 (1-3) 4 (0-8)
Total delay from symptom onset to assess-
ment by Rheumatologist, median (IQR),
weeks
21 (13-63) 25 (14-53) 22 (15-32) 27 (19-43) 35 (14-74) 25 (12-77) 20 (13-36) 38 (16-192)
P value across levels of delay 1-4a <0.0001 <0.0001 <0.0001 <0.0001 0.0028 <0.0001 <0.0001 <0.0001
aKruskal Wallis test comparing across levels of delay 1-4.
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159. DAS28 USING CRP IS SIGNIFICANTLY LOWER THAN
DAS28 ESR IN RA PATIENTS
Claire Sheehy1, Alexa Shipman1, Irina Stech1 and Chetan Mukhtyar1
1Rheumatology, Norfolk and Norwich University Hospital, Norwich,
United Kingdom
Background: The disease assessment score 28 joint count (DAS28) is
a validated tool to assess disease activity in rheumatoid arthritis (RA)
and is widely used in clinical trials. The original DAS28 has four
components: tender joint count, swollen joint count, visual analogue
score (VAS) of the patient’s global health and erythrocyte sedimenta-
tion rate (ESR). Versions of DAS28 which substitute C-reactive protein
(CRP) instead of the ESR have been developed because CRP is not
affected by age, gender and globulin levels. A three variable DAS28
without the VAS is also available. A DAS28 2.6 has been proposed as
remission and 5.1 as high disease activity. It is recognised that the
DAS28 CRP values tend to be lower than the DAS28 ESR values but
the quantum of difference is unknown. We aimed to quantify the
difference and find the equivalent values for ‘remission’ and ‘high
disease activity’ in the versions using the CRP.
Methods: Consecutive outpatient letters from general rheumatology
and biologics clinic were reviewed. Data collected included swollen
joint count, tender joint, global health assessment, ESR and CRP. If
any of these variables was not described, or the inflammatory markers
had not been measured, then the letter was disregarded. Four versions
of the DAS28 score were then calculated i.e. the DAS28 ESR 4
variables (4V), DAS28 CRP 4V, DAS28 ESR 3 variables (3V) and DAS28
CRP 3V. Statistical analysis was performed using SPSS 17.0;
descriptive statistics, paired t-tests, and Spearman’s rank correlation
tests were applied as appropriate. Receiver operating characteristic
(ROC) curves were then constructed to find corresponding values of
DAS28 CRP 3V, DAS28 CRP 4V and DAS28 ESR3V, for DAS28 ESR
4V values of 2.6 and 5.1.
Results: 366 patients with RA were analysed. The mean DAS28 ESR
4V of 3.59 differed significantly from the mean DAS28 CRP 4V of 3.00
(p<0.001), DAS28 CRP 3V of 3.15 (p<0.001), and DAS28 ESR 3V of
3.80 (p<0.001). All 4 versions of the DAS28 were shown to be
significantly correlated (using Spearman’s correlation) with each other,
p<0.001 for all comparisons. Values corresponding to DAS28 ESR 4V
values of 2.6 and 5.1 are as in Table 1.
Conclusions: There is a strong correlation between all 4 versions of
the DAS28, but the versions using CRP have statistically significant
and clinically meaningful lower values. This should be borne in mind at
a time that we are being encouraged to treat all of our patients DAS
targets, as the inflammatory marker used will have significant impact
on the ultimate DAS score.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
DAS28 CRP 4V DAS28 CRP 3V DAS28 ESR 3V
DAS28
ESR 4V
Value Sens Spec Value Sens Spec Value Sens Spec
5.1 4.135 95.8% 95.6% 4.445 94.4% 94.9% 5.09 97.2% 95.6%
2.6 1.89 88.1% 87.0% 2.150 88.1% 87.8% 2.98 97.0% 99.2%
Sens: sensitivity; Spec: specificity
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ARTHRITIS: FROM ENDOTHELIAL DYSFUNCTION TO
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Background: Rheumatoid arthritis (RA) is characterized by an
increase in cardiovascular (CV) mortality compared to the general
population. Endothelial dysfunction begins early after the onset of the
disease and plays a pathogenetic role in the development of accele-
rated atherosclerosis. An impaired coronary flow reserve (CFR<2.5)
has been proved to detect an early impairment of coronary micro-
circulation before the onset of clinical evidence of CV disease. Our
objective was to evaluate the relationship between CFR, common
carotid intima-media thickness (IMT) and asymmetric dimethylarginine
(ADMA) in RA patients.
Methods: 120 adult patients with RA who fulfilled the ACR classifica-
tion criteria [M 20 (16.6%), F 100 (83.4%)], mean age 6113 years)
without clinical evidence of CV disease underwent standard echo-
cardiography and dypiridamole stress echo was performed to evaluate
CFR in the left descending coronary artery. Carotid ultrasound was
performed to evaluate common carotid IMT and a blood sample was
collected to measure plasma ADMA levels.
Results: 72/120 patients (60%) had CFR<2.5 of which 14/120 (12%)
had CFR<2. All patients had normal wall motion at rest and during
stress. Common carotid IMT was in normal range (0.730.13 mm)
while plasma ADMA levels were increased (0.720.10). Linear
regression analysis showed a significant negative correlation between
CFR and common carotid IMT (P<0.001), plasma ADMA levels
(P<0.001) and patient’s age (P¼ 0.019). Moreover, CFR resulted
negatively related with rheumatoid factor levels (P¼ 0.0009) and visual
analogue score (VAS) (P¼ 0.0092).
Conclusions: RA patients without clinical evidence of CV diseases
showed an early impairment of coronary microcirculation and
endothelial dysfunction before structural changes of large vessels
occur. This suggests that reduced CFR is an early marker of enhanced
atherosclerosis in a preclinical stage and it is associated with
endothelial dysfunction. Moreover, indexes of disease activity resulted
negatively associated with coronary microcirculation function
Disclosure statement: The authors have declared no conflicts of
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161. RARE AND OPPORTUNISTIC INFECTIONS IN PATIENTS
EXPOSED TO ANTI-TNF THERAPY: RESULTS FROM THE
BSR BIOLOGICS REGISTER (BSRBR)
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TABLE 1. Baseline characteristics and incidence of infections
DMARD All anti-TNF ETN INF ADA
Subjects, n 3666 11864 4136 3472 4256
Mean age (S.D.), years 60 (12) 56 (12) 56 (12) 56 (12) 57 (12)
Female gender, n (%) 2648 (72) 9038 (76) 3190 (77) 2624 (76) 3224 (76)
Disease Duration, median (IQR), years 6 (1-15) 11 (6-19) 12 (6-19) 12 (6-19) 10 (5-18)
Baseline steroid use, n (%) 834 (23) 5243 (44) 1977 (48) 1609 (46) 1657 (39)
DAS28, mean (S.D.) 5.1 (1.3) 6.6 (1.0) 6.6 (1.0) 6.6 (1.0) 6.5 (1.0)
Exposure, pyrs 12592 53715 23026 13476 17211
All rare / opportunistic infections: n 5 53 18 21 14
Incidence rate / 10000 pyrs (95% confidence interval) 4.0 (1.3, 9.3) 10.0 (7.4, 12.9) 7.8 (4.6, 12.4) 15.6 (9.6, 23.8) 8.1 (4.4, 13.6)
Bacterial endocarditis: n 1 13 6 3 4
Invasive fungal infection: n 1 4 1 3 0
Legionellosis: n 0 6 0 2 4
Listeriosis: n 1 8 2 4 2
Multidermatomal shingles: n 0 8 3 3 2
Pneumocystis pneumonia: n 1 7 2 3 2
Invasive salmonellosis: n 1 7 4 3 0
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Background: Anti TNF therapy is associated with a small increased
risk of infection. There are biological reasons to expect that certain
infections might be disproportionately increased, especially those
caused by intracellular pathogens.
Methods: The BSRBR was established in 2001 to evaluate the safety
of anti-TNF therapies etanercept (ETN), infliximab (INF) and adalimu-
mab (ADA) in patients with RA. The anti-TNF treated cohort was
recruited alongside a comparator group with active disease (DAS28
>4.2) treated with DMARDs. Patients were recruited between 01/10/
2001 and 30/06/2008 and followed up by consultant and patient
questionnaires until 31/12/2009 or death, whichever came first. The
BSBBR defined a list of opportunistic infections at its outset. In
addition to these, we included infective endocarditis. Tuberculosis was
excluded from this analysis as we have reported on this previously.
Results: 11 864 anti-TNF and 3666 DMARD patients were included
(Table 1). 58 rare or opportunistic infections were identified during the
follow up (Anti-TNF 53; DMARD 5). The absolute rates of these
infections were low in both cohorts (anti-TNF 10/10000 patient years
follow up (pyrs); DMARD 4/10000 pyrs). Within the anti-TNF cohort,
endocarditis was the most frequent event (13/53). The other reported
opportunistic infections in the anti-TNF cohort were: invasive fungal
infection (2 aspergillus, 2 candida), legionellosis (6), listeriosis (8),
multidermatomal shingles (8), pneumocystis pneumonia (7), and
invasive salmonellosis (7). These events were distributed amongst
patients on each of the 3 anti-TNF agents.
Conclusions: The crude rate of rare or opportunistic infections and
in particular endocarditis, was higher in anti-TNF exposed patients. We
cannot conclude whether this is directly attributable to the anti-TNF
therapy itself or other confounders, such as concurrent corticosteroid
exposure. The clinician managing a sick patient on anti-TNF therapy
should be aware of this spectrum of infection.
Funding: The BSRBR is supported by a research grant from the British
Society for Rheumatology.
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162. FINE SPECIFICITY OF ANTI-CITRULLINATED PEPTIDE
ANTIBODIES IS ASSOCIATED WITH RESPONSE TO ANTI-TNF
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Background: Anti-CCP antibodies have been associated with a
poorer response to anti-TNF agents in RA. However, CCP is not an
autoantigen but a group of synthetic peptides designed to maximise
diagnostic sensitivity and which may fail to differentiate important
disease subsets. We examined whether antibodies to immunodomi-
nant epitopes from three candidate citrullinated autoantigens could
further define a subset of RA patients with a poor response to anti-
TNF.
Methods: Samples from 450 patients enrolled in the British Society of
Rheumatology Biologics Register were analysed for antibodies to
CCP2 and to peptides from citrullinated a-enolase (CEP-1), vimentin
(cVim) and fibrinogen (cFib). Associations with change in DAS28
scores at 6 months were analysed by linear regression, and with
EULAR response criteria by ordinal logistic regression.
Results: Anti-CEP-1, anti-cVim, anti-cFib and anti-CCP antibodies
were present in 39%, 42%, 75% and 84% respectively. Anti-cFib
antibodies were associated with a poorer response to anti-TNF
therapy at 6 months using linear regression adjusted for baseline
characteristics, and with a trend towards lower EULAR response. The
subset with antibodies to both anti-CCP and anti-cFib antibodies had
a worse outcome (linear regression coefficient for DAS28 score at 6
months 0.55; 95% CI 0.13, 0.97; p¼ 0.01) than the anti-cFib-/CCPþ
subset (coefficient 0.31; 95% CI -0.24, 0.87; p¼0.27) when compared
to those negative for both antibodies. The presence of anti-CEP-1 and
anti-cVim antibodies was not associated with a poorer response.
Conclusions: The association of anti-cFib antibodies with a poorer
response to anti-TNF therapy justifies further investigation of anti-
bodies to specific citrullinated antigens as predictors of clinical
outcomes in RA.
Disclosure statement: K.L. and P.V. own a patent on the use of CEP-
1 peptide. All other authors have declared no conflicts of interest.
163. DOES ROUTINE MUSCULOSKELETAL ULTRASOUND
USE ADD VALUE TO THE DIAGNOSIS OF RA AMONG EARLY
UNDIFFERENTIATED ARTHRITIS PATIENTS?
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Background: It remains to be demonstrated whether, in an early
arthritis clinic, a system of routine MSUS evaluation may be
implemented that adds value to more readily available clinical and
laboratory predictors for diagnosing RA amongst UA patients.
Methods: A small joint MSUS screening protocol was devised, which
focussed on 16 small joints of the upper and lower limbs, but had
flexibility to incorporate additional joints as directed by clinical
symptoms and signs. A validated, semi-quantitative score adapted
from published systems was used to record findings for 3 MSUS
‘‘domains’’ at each joint site: effusion / grey-scale synovitis, power
Doppler and erosions. Consenting UA patients attending an early
arthritis clinic were followed up for >1 year (median 28 months); those
for whom a definitive outcome diagnosis was not reached within the
study period (1987 ACR classification criteria required for RA) were
excluded. Optimum baseline MSUS parameters (and cut-offs) for
independently predicting RA were identified. An ‘‘RA prediction score’’
was developed using baseline clinical and laboratory predictors (but
not MSUS), according to an approach described previously by others
[1]. The discriminatory utility of this score for RA versus non-RA
outcomes was compared to that of a similarly derived score that did
incorporate the optimum MSUS parameters.
Results: Data for 90 UA patients were analysed, of whom 33 (37%)
developed RA. Out of 25 non-MSUS clinical and laboratory variables at
baseline, 11 were found to differ significantly between RA and non-RA
outcomes; 7 of these (SJC, joint pattern score, ESR, ACPA, RF, IgA
and Ferritin) contributed to a final prediction score, which had an
excellent ability to discriminate RA from non-RA outcome (area under
ROC curve¼ 0.95; SEM¼ 0.029; p< 0.001). The best independent
MSUS predictors of RA outcome were grey-scale synovitis score 1
for 16 joints and power Doppler synovitis score 3 for all examined
joints. These 2 variables were incorporated into the development of a
modified prediction score comprising 6 variables (SJC, joint pattern
score, ESR, ACPA, Ferritin and power Doppler synovitis). The ability of
the modified score to discriminate RA from non-RA outcomes in the
current cohort was virtually identical to that of the score derived
without the benefit of MSUS (area under ROC curve¼0.95; SEM
0.029; p<0.001).
Conclusions: Our data imply that the incorporation of routine MSUS
into early arthritis clinics as a diagnostic adjunct may not be essential
for optimally diagnosing RA amongst patients who present with UA.
Refinement of MSUS screening protocols and stratification of the UA
population may yet delineate a clearer clinical role for MSUS in this
setting.
Disclosure statement: The authors have declared no conflicts of
interest.
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